Overview
Ovagen (EDG) is a synthetic peptide bioregulator developed specifically to normalize and restore the digestive tract, liver, gallbladder, and pancreatic systems.
What problem it targets: It targets chronic digestive distress, hepatitis, fatty liver infiltration, sluggish gallbladder bile flow, gastritis, and poor nutrient absorption.
What It Does
• Restores gastrointestinal mucosal lining: Stimulates cellular division and repair across the epithelial lining of the stomach and small intestine, resolving gut irritation.
• Enhances liver hepatocyte function: Upregulates protein synthesis in liver cells, improving bile secretion and aiding the processing of dietary fats and toxins.
• Optimizes digestive enzyme secretion: Coordinates balanced digestive enzyme release between the liver, gallbladder, and pancreas to alleviate bloating and indigestion.
• Realistic expectations: Typically run in 10- to 20-day courses. Delivers progressive, long-lasting improvements in daily digestive comfort, food tolerance, and liver blood markers.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 20 mg (assumed vial strength) | 2 mL bacteriostatic water (requested mixing example) | 10 mg/mL = 10,000 micrograms/mL |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Presentation
20 mg vial used for the mixing example. Other sizes exist. Confirm the actual peptide content and sequence on the batch documentation.
Protocol
Community protocols & cycle timing
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Common community cycle pattern | 10–20 consecutive days; a few courses per year with months between courses | Compound- and formulation-specific; see rows below | A shared cycle duration does not establish one shared dose. Oral labels may specify 30-day initial courses or 10-day maintenance courses. |
Research study amounts
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Rat kidney tissue cultures | Organotypic-culture experiment | Not stated in accessible abstract | 2015 EDL/T-35 study; cell-renewal markers, not a human liver or ovarian outcome. |
About these protocols
The community rows describe reported experience, not a standard or recommended human regimen. Product-label rows apply to the cited formulation; cell and animal rows describe research models. The 20 mg / 2 mL table is a concentration example using the requested assumptions. Solvent compatibility and stability are product-specific.
Handling & Stacking
- Bioregulators are often discussed as short 10–20-day courses, repeated a few times a year with months between courses, rather than continuous daily use.
- This describes a community cycle pattern, not one universal dose.
- Some finished oral products instead specify a 30-day course or 10-day maintenance course.
- Where users report subcutaneous administration, the abdomen or outer thigh are common subcutaneous sites.
- This does not establish an approved administration route for this compound.
- No compound-specific universal storage temperature or post-mixing stability period was verified.
- Use the supplier’s stability data for that formulation.
- Keep identity, lot, preparation date and final concentration traceable; a purity percentage alone does not establish sterility or stability.
- The named preparation is not established here as an approved treatment for its marketed goals.
- Approved alternatives depend on the diagnosed condition and cannot be assigned from an organ label alone.
